Bioline RX Ltd (NASDAQ:BLRX) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Bioline RX Ltd (NASDAQ:BLRX) to Hold in a statement released on 10/11/2016.

On 8/15/2016, Zacks Investment Research released a statement on Bioline RX Ltd (NASDAQ:BLRX) upped the target price from $0.00 to $1.00 that suggested an upside of 0.14%.

Having a price of $1.11, Bioline RX Ltd (NASDAQ:BLRX) traded -4.35% lower on the day. With the last close up 18.85% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. BLRX has recorded a 50-day average of $1.01 and a two hundred day average of $0.93. Trade Volume was down over the average, with 89,935 shares of BLRX changing hands under the typical 395,655

Recent Performance Chart

Bioline RX Ltd has with a one year low of $0.71 and a one year high of $1.73 and has a market capitalization of $0.

A total of 3 analysts have released a report on Bioline RX Ltd. zero analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $4.67.

General Company Details For Bioline RX Ltd (NASDAQ:BLRX)

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.